Does erenumab suspension affect chronic migraine course? A real life experience
Does erenumab suspension affect chronic migraine course? A real life experience
Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment - The Lancet Neurology
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts | The Journal of Headache and Pain | Full Text
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study | The Journal of Headache and Pain | Full Text
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
Vi spiego perché Aimovig è la soluzione più efficace» - Trento - Il nuovo Trentino
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Erenumab Tied to Rapid Conversion From Chronic to Acute Migraine
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study - Bianca Raffaelli, Maria Terhart, Lucas Hendrik Overeem, Jasper Mecklenburg, Lars Neeb, Maureen Steinicke, Uwe Reuter, 2022
PDF) Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
PDF) Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
PDF) A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine
Emicrania da otto anni «Finalmente una cura»
Does erenumab suspension affect chronic migraine course? A real life experience
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts | The Journal of Headache and Pain | Full Text
Basta una iniezione ogni 28 giorni, al Mondino la nuova cura contro l'emicrania - La Provincia Pavese
PDF) Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real‐World Case Series
Headache & Migraine Archives - Medical Conferences
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
